Democratic Underground Latest Greatest Lobby Journals Search Options Help Login
Google

Huffington Post: What Are They Waiting For? (Ed Markey)

Printer-friendly format Printer-friendly format
Printer-friendly format Email this thread to a friend
Printer-friendly format Bookmark this thread
This topic is archived.
Home » Discuss » Editorials & Other Articles Donate to DU
 
unhappycamper Donating Member (1000+ posts) Send PM | Profile | Ignore Wed Jun-01-05 07:39 AM
Original message
Huffington Post: What Are They Waiting For? (Ed Markey)
What Are They Waiting For?
By Ed Markey
5.31.2005

The FDA must not look the other way in the life or death matter of drug company follow-up studies.

In December 2004, the Food and Drug Administration (FDA) announced that AstraZeneca's cancer product, Iressa -- which had been approved through the FDA's accelerated approval process -- was not an effective treatment for most cancer patients. When I first heard about this, I was shocked that more than 15,000 Americans were spending about $1,800 a month for a drug that probably wouldn't work in treating their cancer. After asking a few questions about this, what I learned was even more shocking than I had initially imagined.

In 1992, the Food and Drug Administration (FDA) established a process that amounted to a trade-off between its mission to ensure the effectiveness of the treatment and the need to speed promising new drugs to market to increase treatment options for life-threatening illnesses. Called "accelerated approval," this process allows FDA to approve a drug on an expedited basis using promising but limited information about its safety and effectiveness, but only on the condition that the company agrees to conduct further studies to confirm the safety and effectiveness of the product. Under the law, drug companies are required to do additional studies to confirm that the drug is safe, effective and works for its approved indication.

In searching for answers about how Iressa remained on the market, I found that the case of the Iressa was only the tip of the iceberg of the problems existing with the "accelerated approval" process -- approximately half of pharmaceutical companies neglect to complete these critical follow up studies. I am releasing a report today which reveals that of the 91 postmarketing studies required by the FDA, 42 studies have not been completed and half of the unfinished studies have not even started.

(not much) MORE

http://www.huffingtonpost.com/theblog/archive/ed-markey/what-are-they-waiting-for_1920.html
Printer Friendly | Permalink |  | Top

Home » Discuss » Editorials & Other Articles Donate to DU

Powered by DCForum+ Version 1.1 Copyright 1997-2002 DCScripts.com
Software has been extensively modified by the DU administrators


Important Notices: By participating on this discussion board, visitors agree to abide by the rules outlined on our Rules page. Messages posted on the Democratic Underground Discussion Forums are the opinions of the individuals who post them, and do not necessarily represent the opinions of Democratic Underground, LLC.

Home  |  Discussion Forums  |  Journals |  Store  |  Donate

About DU  |  Contact Us  |  Privacy Policy

Got a message for Democratic Underground? Click here to send us a message.

© 2001 - 2011 Democratic Underground, LLC